首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1448295

全球妊娠毒血症診斷市場規模、佔有率和成長分析：按測試類型、按產品、最終用戶分類 - 產業預測 (2024-2031)

Global Preeclampsia Diagnostics Market Size, Share, Growth Analysis, By Test type(Blood Tests, and Urine Analysis), By Product(Instruments, and Consumables), By End User(Hospitals, Specialty Clinics) - Industry Forecast 2024-2031

出版日期: 2024年03月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球妊娠毒血症診斷市場規模將達到10.7億美元，從2023年的11.1億美元成長到2031年的15億美元，並將從2023年的11.1億美元成長到2031年的15億美元。預測期內(2024~2031)預計將以3.8% 的複合年成長率成長。

妊娠毒血症診斷已在全世界廣為人知，導致市場顯著成長。被稱為妊娠毒血症的高血壓疾病仍然是產科護理中的一個主要問題，增加了對準確和及時診斷技術的需求。這迫使該行業的主要參與企業專注於開發尖端診斷工具，以實現妊娠毒血症的早期診斷和治療。

妊娠毒血症診斷市場的成長也受到醫療保健成本上升、新興市場醫療保健基礎設施改善以及將尖端醫療技術融入產科醫療程序的支持。

然而，尖端診斷技術的高成本以及某些地區獲得優質醫療保健的機會有限等問題可能會阻礙市場擴張。隨著研究人員探索新的生物標記和非侵入性診斷技術，妊娠毒血症診斷市場預計將在未來幾年進一步發展。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭格局

前5名企業對比
主要企業市場定位（2021年）
主要市場參與者所採取的策略
關鍵成功策略
近期市集活動
主要企業市場佔有率（2021年）

主要企業簡介

F. Hoffmann-La Roche Ltd（Switzerland）
PerkinElmer Inc.（Massachusetts, US）
DRG INSTRUMENTS GMBH（Germany）
Thermo Fisher Scientific Inc.（US）
Diabetomics, Inc.（US）
Metabolomic Diagnostics Ltd.（Ireland）
Sera Prognostics（US）
Siemens Healthineers AG（Germany）
Bayer AG（Germany）
Abbott Laboratories（US）
Agilent Technologies, Inc.（US）
Bio-Rad Laboratories, Inc.（US）
Danaher Corporation（US）
Illumina, Inc.（US）
Natera, Inc.（US）
GE Healthcare（US）
Medtronic plc（Ireland）
Fujifilm Holdings Corporation（Japan）
Mindray Bio-Medical Electronics Co., Ltd.（China）
AstraZeneca plc（UK）

簡介目錄

Product Code: SQMIG35D2145

Global Preeclampsia Diagnostics Market size was valued at USD 1.07 Billion in 2022 and is poised to grow from USD 1.11 Billion in 2023 to USD 1.50 Billion by 2031, growing at a CAGR of 3.8% in the forecast period (2024-2031).

Preeclampsia diagnostics are becoming more widely known worldwide, which is contributing to a noticeable increase in the market. The hypertension condition known as preeclampsia is still a major problem in obstetrics, which is driving up need for precise and timely diagnostic techniques. This has forced major industry participants to concentrate on creating cutting-edge diagnostic tools that allow for the early diagnosis and treatment of preeclampsia.

Preeclampsia diagnostics market growth is also being aided by increased healthcare spending, bettering healthcare infrastructure in developing nations, and integrating cutting-edge medical technology into obstetric care procedures.

But issues like the expensive price of cutting-edge diagnostic techniques and some areas' restricted access to high-quality healthcare could potentially impede market expansion. In the upcoming years, more developments in the preeclampsia diagnostics market are anticipated as researchers carry out their investigation into new biomarkers and non-invasive diagnostic techniques.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Preeclampsia Diagnostics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Preeclampsia Diagnostics Market Segmental Analysis

Market segmentation for preeclampsia diagnostics is based on test type, product, end-user, and region worldwide. It is separated into two categories: urine analysis and blood tests. Consumables and Instruments are included in the product segment. Hospitals, specialty clinics, diagnostic centers, and others are among the end users. The market is divided into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America based on geographic factors.

Drivers of the Global Preeclampsia Diagnostics Market

It has long been difficult to identify hypertension problems in pregnant women in an early stage. The need for novel preeclampsia diagnostic techniques is increasing due to the rise in preeclampsia cases and the urgent need to reduce the rates of maternal and newborn mortality. Point-of-care tests have emerged to diagnose preeclampsia early and have the potential to reduce avoidable hospital hospitalizations and their associated expenses. Major market participants are collaborating strategically to provide better diagnostic solutions in order to address the risk of premature birth. Throughout the anticipated period, the market's trajectory is anticipated to be driven by a wave of product introductions and changing biomarker testing.

Restraints in the Global Preeclampsia Diagnostics Market

Preeclampsia in pregnant women is difficult to diagnose because a single rise in blood pressure is inconclusive. Many expectant women are still ignorant of the term "preeclampsia" and its dangers, despite its rising incidence. Pregnancy-related hypertension frequently goes undiagnosed until symptoms increase, which reduces the number of management choices. at addition to putting women's health at jeopardy, this ignorance about the condition's symptoms and effects raises the risk of newborn mortality.

Market Trends of the Global Preeclampsia Diagnostics Market

A Growing Priority for Early Risk Assessment A significant and noteworthy development in the worldwide preeclampsia diagnostics market is the growing focus on early risk assessment in expectant mothers. The increasing use of biomarker-based testing for the early diagnosis of preeclampsia is being driven by this trend. By utilizing particular biological markers linked to the condition, these tests allow medical professionals to detect possible preeclampsia instances early on. By being proactive, the disease can be better managed and prompt interventions can help improve the results for both the mother and the fetus. The use of biomarker-based diagnostics is in line with the larger goal of lessening the effect of preeclampsia on maternal health and pregnancy outcomes as healthcare systems work to improve maternal care.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Preeclampsia Diagnostics Market by Test type

Market Overview
Blood Tests
and Urine Analysis

Global Preeclampsia Diagnostics Market by Product

Market Overview
Instruments
and Consumables

Global Preeclampsia Diagnostics Market by End User

Market Overview
Hospitals
Specialty Clinics
Diagnostic Centers & Others

Global Preeclampsia Diagnostics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer Inc. (Massachusetts, US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DRG INSTRUMENTS GMBH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Diabetomics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Metabolomic Diagnostics Ltd. (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sera Prognostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm Holdings Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mindray Bio-Medical Electronics Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments